SOURCE: Equity News Circuit

Equity News Circuit

May 08, 2013 08:45 ET

Free Research Reports on GNK, MHR, PTIE and SNTA Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit

NEW YORK, NY--(Marketwired - May 8, 2013) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Genco Shipping & Trading Ltd. (NYSE: GNK) shares fell 18.6 percent on volume of over 6.0 million shares traded Tuesday. The company reported their net loss grew to $48.2 million, or $1.12 per share basic and diluted, for the first quarter of 2013, from $33.1 million, or $0.87 per share basic and diluted, a year ago.

Find out more about Genco Shipping & Trading including full access to the free equity report at: www.BedfordReport.com/GNK

Magnum Hunter Resources Corp. (NYSE: MHR) shares surged nearly 8.0 percent on volume of over 4.0 million shares traded Tuesday. The company announced that its subsidiary, Alpha Hunter Drilling, LLC, has acquired a new robotic drilling rig for use in the Utica formation for the next three years.

Find out more about Magnum Hunter Resources including full access to the free equity report at: www.BedfordReport.com/MHR

Pain Therapeutics, Inc. (NASDAQ: PTIE) shares spiked roughly 15.0 percent on more than double the average daily volume Tuesday. The WSJ recently reported that a large number of pharmaceutical companies are looking to develop painkillers that are abuse proof following the FDA's decision to block the sale of a generic version of OxyContin, which was easier to "abuse" than the original.

Find out more about Pain Therapeutics including full access to the free equity report at: www.BedfordReport.com/PTIE

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) shares declined 14.0 percent on more than nine times the average daily volume Tuesday. BMO Capital has recently downgraded the biotech company's rating to "market perform" from "outperform" and has also slashed its price target to $9.00 from $18.00.

Find out more about Synta Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/SNTA

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information